HUP9801872A2 - Valaciclovir tablets containing colloidal silicon dioxide and process for producing them - Google Patents

Valaciclovir tablets containing colloidal silicon dioxide and process for producing them

Info

Publication number
HUP9801872A2
HUP9801872A2 HU9801872A HUP9801872A HUP9801872A2 HU P9801872 A2 HUP9801872 A2 HU P9801872A2 HU 9801872 A HU9801872 A HU 9801872A HU P9801872 A HUP9801872 A HU P9801872A HU P9801872 A2 HUP9801872 A2 HU P9801872A2
Authority
HU
Hungary
Prior art keywords
silicon dioxide
producing
valaciclovir
colloidal silicon
tablets containing
Prior art date
Application number
HU9801872A
Other languages
Hungarian (hu)
Inventor
Barry Howard Carter
Lloyd Gary Tillman
Original Assignee
The Wellcome Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9801872(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Ltd. filed Critical The Wellcome Foundation Ltd.
Publication of HUP9801872A2 publication Critical patent/HUP9801872A2/en
Publication of HUP9801872A3 publication Critical patent/HUP9801872A3/en
Publication of HU226131B1 publication Critical patent/HU226131B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya tabletta, amely az alábbiakat tartalmazza: legalábbkb. 50 tömeg% valaciclővir vagy sója, egy töltőanyag, egy kötőanyag,egy kenőanyag és kb. 0,05- kb. 3 tömeg% kőllőidális szilíciűm-diőxid,ahől a valaciclővir vagy sója a tabletta granűlátűmaiban helyezkedikel, és a kenőanyag és a szilíciűm-diőxid extragranűlárisan; a tablettapőrlékőnysága nem haladja meg az 1%-őt, keménysége legalább 8 kP, és akilökési erő nem haladja meg az 1000 N-t. A találmány tárgyát képezi afenti tabletta előállítására szőlgáló eljárás is. ŕThe subject of the invention is a tablet containing the following: at least approx. 50% by weight of valaciclovir or its salt, a filler, a binder, a lubricant and approx. 0.05- approx. 3% by weight of crystalline silicon dioxide, from which valaciclovir or its salt is located in the granule spaces of the tablet, and the lubricant and silicon dioxide are extragranular; the tablet's powder elasticity does not exceed 1%, its hardness is at least 8 kP, and its impact force does not exceed 1000 N. The subject of the invention is also a vinification process for the production of Afenti tablets. ŕ

HU9801872A 1995-01-20 1996-01-19 Valaciclovir tablets containing colloidal silicon dioxide and process for producing them HU226131B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet
PCT/GB1996/000111 WO1996022082A1 (en) 1995-01-20 1996-01-19 Valaciclovir tablets containing colloidal silicon dioxide

Publications (3)

Publication Number Publication Date
HUP9801872A2 true HUP9801872A2 (en) 1999-10-28
HUP9801872A3 HUP9801872A3 (en) 2001-02-28
HU226131B1 HU226131B1 (en) 2008-05-28

Family

ID=10768317

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801872A HU226131B1 (en) 1995-01-20 1996-01-19 Valaciclovir tablets containing colloidal silicon dioxide and process for producing them

Country Status (39)

Country Link
US (1) US5879706A (en)
EP (1) EP0806943B1 (en)
JP (1) JP3350055B2 (en)
KR (1) KR100412298B1 (en)
CN (2) CN1131026C (en)
AP (1) AP666A (en)
AT (1) ATE190483T1 (en)
AU (1) AU710823B2 (en)
BG (1) BG63187B1 (en)
BR (1) BR9606769A (en)
CA (1) CA2210891C (en)
CY (1) CY2182B1 (en)
CZ (1) CZ296514B6 (en)
DE (1) DE69607146T2 (en)
DK (1) DK0806943T3 (en)
EA (1) EA000276B1 (en)
EE (1) EE03336B1 (en)
ES (1) ES2145425T3 (en)
FI (1) FI119722B (en)
GB (1) GB9501127D0 (en)
GE (1) GEP20022752B (en)
GR (1) GR3033677T3 (en)
HK (1) HK1002851A1 (en)
HU (1) HU226131B1 (en)
IL (1) IL116830A (en)
IN (1) IN181318B (en)
MY (1) MY126346A (en)
NO (1) NO311488B1 (en)
NZ (1) NZ298846A (en)
OA (1) OA10500A (en)
PL (1) PL185307B1 (en)
PT (1) PT806943E (en)
RO (1) RO118175B1 (en)
SK (1) SK282030B6 (en)
TR (1) TR199700657T1 (en)
UA (1) UA68325C2 (en)
UY (2) UY25774A1 (en)
WO (1) WO1996022082A1 (en)
ZA (1) ZA96448B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
ES2210490T3 (en) * 1996-01-19 2004-07-01 Glaxo Group Limited USE OF VALACICLOVIR FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF GENITAL HERPES BY A SINGLE DAILY ADMINISTRATION.
AR017512A1 (en) * 1997-08-22 2001-09-12 Smithkline Beecham Corp TABLETS OF QUICKLY DISPOSABLE METILCELLULOSE FOR ORAL ROUTE ADMINISTRATION AND PROCEDURE TO PREPARE THEM
AR016827A1 (en) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL TABLET
DK1140034T3 (en) * 1998-12-18 2004-03-08 Abbott Lab Controlled release divalproex sodium formulation
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
EA005949B1 (en) * 2001-05-01 2005-08-25 Пфайзер Продактс Инк. Method for manufacturing a low dose pharmaceutical composition
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US20040197396A1 (en) * 2001-11-05 2004-10-07 Fain Helen S Anhydrous crystal form of valaciclovir hydrochloride
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ES2270172T3 (en) * 2002-10-16 2007-04-01 Teva Pharmaceutical Industries Ltd. PROCEDURE TO REDUCE RESIDUAL ALCOHOLS IN VALACICLOVIR CRISTALINO HYDROCLORIDE.
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
KR100871621B1 (en) * 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 Novel crystalline forms of valacyclovir hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
HUE044279T2 (en) 2003-09-12 2019-10-28 Amgen Inc Rapid dissolution formulation of cinacalcet hcl
DE10351448A1 (en) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Flavor-containing drug formulations with improved pharmaceutical properties
DE60301277T2 (en) * 2003-12-09 2006-03-30 Helm Ag PHARMACEUTICAL PREPARATION CONTAINING VALACICLOVIR
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (en) 2004-12-06 2012-02-22 에스케이케미칼주식회사 Pharmaceutical composition of amlodipine maleate with improved stability
DK1868579T3 (en) 2005-03-07 2011-01-10 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl sun-substituted diphenylurea for the treatment of cancer
ATE546451T1 (en) * 2005-05-25 2012-03-15 Lilly Co Eli CYCLOPROPANE CARBONIC ACID ESTERS OF ACYCLOVIR
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
WO2007128350A1 (en) * 2006-05-10 2007-11-15 Evonik Degussa Gmbh Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
EP2037887B1 (en) * 2006-05-31 2010-09-15 Vertex Pharmaceuticals Incorporated Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor
EP2040684B1 (en) * 2006-07-11 2013-01-23 LEK Pharmaceuticals d.d. Multiple unit tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (en) * 2008-01-18 2009-07-19 Maria Balestrieri USE OF ACICLOVIR FOR THE TREATMENT OF CONDILOMATOSIS.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
DK2407166T3 (en) * 2009-03-13 2013-10-07 Toyama Chemical Co Ltd Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazine carboxamide
CH703348A1 (en) * 2010-06-29 2011-12-30 Mepha Gmbh Compositions having a high active ingredient content of pharmaceutically active substances.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (en) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 Solid preparations containing Pelargonium sidoides extracts and silicic acid compound, and preparing method thereof
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (en) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 Valaciclovir hydrochloride tablet and preparation method thereof
JP2023551524A (en) * 2020-12-01 2023-12-08 エルジー・ケム・リミテッド Oral preparation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid and method for producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
ES2052911T3 (en) * 1988-05-04 1994-07-16 Smith Kline French Lab CHEWABLE TABLET.
DE4290300T1 (en) * 1991-01-30 1993-10-07 Wellcome Found Water dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet

Also Published As

Publication number Publication date
WO1996022082A1 (en) 1996-07-25
DE69607146T2 (en) 2000-09-21
UY25778A1 (en) 2000-08-21
KR19980701524A (en) 1998-05-15
PL185307B1 (en) 2003-04-30
IN181318B (en) 1998-05-09
BG101831A (en) 1998-04-30
FI973062A0 (en) 1997-07-18
GEP20022752B (en) 2002-08-26
NZ298846A (en) 1998-06-26
AP9701057A0 (en) 1997-10-31
NO973327D0 (en) 1997-07-18
CZ229297A3 (en) 1998-02-18
AU710823B2 (en) 1999-09-30
CN1494898A (en) 2004-05-12
IL116830A0 (en) 1996-05-14
GR3033677T3 (en) 2000-10-31
FI973062A (en) 1997-09-18
UA68325C2 (en) 2004-08-16
FI119722B (en) 2009-02-27
MY126346A (en) 2006-09-29
CN1179100A (en) 1998-04-15
JPH10512564A (en) 1998-12-02
BG63187B1 (en) 2001-06-29
CA2210891A1 (en) 1996-07-25
CN1131026C (en) 2003-12-17
TR199700657T1 (en) 1998-02-21
EA000276B1 (en) 1999-02-25
UY25774A1 (en) 2000-10-31
RO118175B1 (en) 2003-03-28
CY2182B1 (en) 2002-08-23
AP666A (en) 1998-08-24
PL321361A1 (en) 1997-12-08
KR100412298B1 (en) 2004-04-21
CN1313081C (en) 2007-05-02
EP0806943B1 (en) 2000-03-15
NO973327L (en) 1997-09-16
GB9501127D0 (en) 1995-03-08
ATE190483T1 (en) 2000-04-15
HU226131B1 (en) 2008-05-28
EA199700123A1 (en) 1997-12-30
DE69607146D1 (en) 2000-04-20
ZA96448B (en) 1996-08-07
NO311488B1 (en) 2001-12-03
CZ296514B6 (en) 2006-03-15
OA10500A (en) 2002-04-10
IL116830A (en) 2000-02-29
DK0806943T3 (en) 2000-07-24
EP0806943A1 (en) 1997-11-19
CA2210891C (en) 2009-05-19
BR9606769A (en) 1997-12-30
MX9705459A (en) 1997-10-31
SK282030B6 (en) 2001-10-08
EE03336B1 (en) 2001-02-15
US5879706A (en) 1999-03-09
HK1002851A1 (en) 1998-09-25
AU4453496A (en) 1996-08-07
JP3350055B2 (en) 2002-11-25
HUP9801872A3 (en) 2001-02-28
SK96497A3 (en) 1998-01-14
PT806943E (en) 2000-08-31
ES2145425T3 (en) 2000-07-01

Similar Documents

Publication Publication Date Title
HUP9801872A2 (en) Valaciclovir tablets containing colloidal silicon dioxide and process for producing them
ES2018113A6 (en) 4H-1-benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
DZ1792A1 (en) A new form of compound.
CA2031714A1 (en) R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
HUP0103844A2 (en) Sustained release ranolazine formulations
CA2232310A1 (en) Stable compositions containing n-propargyl-1-aminoindan
CA2166483A1 (en) New Pharmaceutical Formulation
CA2032068A1 (en) Pharmaceutical lozenges
AU5861499A (en) Agitation-independent pharmaceutical multiple unit retard preparations and method for the production thereof
WO1992020649A3 (en) Substituted 2-carboxyindoles having pharmaceutical activity
AU574024B2 (en) Polycaprolactone matrix for oral drug administration
CA2112084A1 (en) Antidepressant and antiparkinsonian compounds
IL105276A (en) (S)-a-PHENYL- 2-PYRIDINEETHANAMINE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CA2306508A1 (en) Production of a directly compressible tabletting aid
RU92004562A (en) NEW CEPHALOSPORINES, HAVING A SUBSTITUTED OXYIMINAL RADICAL IN POSITION 7, METHOD OF THEIR RECEIVING AND THEIR USE AS MEDICAL DOCUMENTS
HUP0202228A2 (en) Low-dose tablets and preparation method
AU4328996A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
HUP9904077A2 (en) Crystalline pharmaceutical product
HUP9901021A2 (en) High-content famciclovir pharmaceutical tablets
WO1996033723A3 (en) Use of benzamide derivatives for treating and/or preventing meniere's syndrome and motion sickness
CA2084109A1 (en) Novel process for preparing 4-amino-5-hexanoic acid
AU4329196A (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
TH27441EX (en) Pager receiver
TH27282EX (en) Cartridge for game consoles
TH20745EX (en) Pill

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees